OLD National Bancorp IN purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the first quarter, HoldingsChannel.com reports. The institutional investor purchased 1,213 shares of the company’s stock, valued at approximately $271,000.
A number of other institutional investors have also modified their holdings of IDXX. Norges Bank bought a new stake in IDEXX Laboratories during the fourth quarter worth $148,632,000. FMR LLC raised its stake in shares of IDEXX Laboratories by 120.7% in the fourth quarter. FMR LLC now owns 561,266 shares of the company’s stock valued at $104,407,000 after buying an additional 306,919 shares during the period. Principal Financial Group Inc. raised its stake in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Principal Financial Group Inc. now owns 787,832 shares of the company’s stock valued at $146,551,000 after buying an additional 291,795 shares during the period. BlackRock Inc. raised its stake in shares of IDEXX Laboratories by 4.6% in the fourth quarter. BlackRock Inc. now owns 6,549,022 shares of the company’s stock valued at $1,218,251,000 after buying an additional 289,208 shares during the period. Finally, Samlyn Capital LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $28,597,000. Institutional investors and hedge funds own 87.46% of the company’s stock.
Several analysts have issued reports on the company. Canaccord Genuity boosted their target price on IDEXX Laboratories from $255.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, April 30th. Finally, Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 target price on the stock in a research note on Friday, May 3rd. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. IDEXX Laboratories has an average rating of “Buy” and a consensus target price of $253.50.
Shares of IDXX opened at $251.97 on Friday. The firm has a market capitalization of $21.47 billion, a price-to-earnings ratio of 59.15 and a beta of 0.97. The company has a debt-to-equity ratio of 14.81, a quick ratio of 0.74 and a current ratio of 1.01. IDEXX Laboratories, Inc. has a 1 year low of $176.11 and a 1 year high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.13. The firm had revenue of $576.06 million for the quarter, compared to analyst estimates of $575.04 million. IDEXX Laboratories had a return on equity of 354,783.84% and a net margin of 17.33%. The business’s revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.01 earnings per share. Research analysts anticipate that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current fiscal year.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Story: What is the return on assets (ROA) ratio?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.